CD19 and acute lymphoblastic leukemia: To simulate a worst-case scenario resembling aggressive CD19- relapse in B-ALL patients, mice were rechallenged with Nalm-6 CD19 KO cells 1-, 2- and 3-weeks post CAR T-cell treatment.